{"id":"NCT00772889","sponsor":"GlaxoSmithKline","briefTitle":"Evaluation of the Safety and Immunogenicity of the Influenza Vaccine GSK2186877A in the Elderly","officialTitle":"Safety and Immunogenicity of the Influenza Vaccine GSK2186877A in the Elderly","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-10-09","primaryCompletion":"2009-12-15","completion":"2009-12-15","firstPosted":"2008-10-15","resultsPosted":"2012-04-24","lastUpdate":"2018-07-31"},"enrollment":971,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"PREVENTION"},"conditions":["Influenza"],"interventions":[{"type":"BIOLOGICAL","name":"Influenza vaccine GSK2186877A","otherNames":[]},{"type":"BIOLOGICAL","name":"GSK Biologicals' Fluarixâ„¢","otherNames":[]}],"arms":[{"label":"New generation influenza vaccine GSK2186877A Group","type":"EXPERIMENTAL"},{"label":"Fluarix elderly Group","type":"ACTIVE_COMPARATOR"},{"label":"Fluarix young Group","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this observer-blind clinical trial is to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals' influenza vaccine GSK2186877A in the elderly. Subjects were previously vaccinated (NCT00529516).","primaryOutcome":{"measure":"Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs)","timeFrame":"Day 0-6","effectByArm":[{"arm":"New Generation Influenza Vaccine GSK2186877A Group","deltaMin":2,"sd":null},{"arm":"Fluarix Elderly Group","deltaMin":3,"sd":null},{"arm":"Fluarix Young Group","deltaMin":1,"sd":null}],"pValues":[]},"eligibility":{"minAge":"19 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":15},"locations":{"siteCount":29,"countries":["United States","Belgium","Germany","Norway"]},"refs":{"pmids":[],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":40,"n":375},"commonTop":["Pain","Fatigue","Myalgia","Headache","Redness"]}}